Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Deoxycytidine Kinase-Independent Cytotoxicity via Gemcitabine Monophosphate Release
- Molecular classification
- Therapeutic strategy, Drug resistance mechanism
01
Overview
Deoxycytidine kinase (dCK)-independent cytotoxicity via gemcitabine monophosphate release refers to a strategy to induce cell death using gemcitabine without relying on the canonical activation step mediated by dCK. This involves delivering gemcitabine monophosphate (dFdCMP) directly or through prodrugs, bypassing dCK and overcoming resistance in tumors with low or absent dCK activity. The downstream effects include incorporation of dFdCTP into DNA, leading to masked chain termination, and inhibition of ribonucleotide reductase by dFdCDP.
- Other names
- dCK-independent gemcitabine cytotoxicityGemcitabine monophosphate deliverydFdCMP-mediated cytotoxicity
02
Mechanism of action
Direct delivery or intracellular release of gemcitabine monophosphate (dFdCMP), bypassing the need for deoxycytidine kinase (dCK) activation.
03
Biological functions
Cell death inductionOvercoming drug resistance
04
Disease associations
CancerDrug resistance
05
Safety considerations
Potential systemic toxicity of dFdCMPDelivery challenges to tumor cellsOff-target effects of prodrug activation
06
Interacting drugs
Gemcitabine
2 more in the full profile.
07
Biomarkers
dCK expression levelsTumor response to gemcitabine
Beyond the preview
Go deeper on Deoxycytidine Kinase-Independent Cytotoxicity via Gemcitabine Monophosphate Release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Deoxycytidine Kinase-Independent Cytotoxicity via Gemcitabine Monophosphate Release.